If you had bought Everest Medicines on 4 November 2025 and simply held on, the past year did not reward your patience. For Everest Medicines shareholders, the loss over the past year was 44.5%, including dividends. That result jars with starting forecasts that leaned on rapid revenue expansion, a swing from deep losses into double digit profit margins, and a much higher future P/E. Which of those specific assumptions proved most fragile, and which still look intact despite the price damage?
Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.
The move put Everest Medicines in the middle of this trade. Scan 127 healthcare AI stocks for other companies exposed to it.
The Two Everest Medicines Stories Investors Had To Weigh
The shares cost HK$48.38 at the start, and Everest Medicines sat between two sharply different but plausible stories.
On the bullish side, the Fair Value sat at HK$62.67, about 30% above the start price. This was built on an assumption of 62.3% revenue growth and profit margins reaching 21.2% within three years.
The bearish camp pointed to a Fair Value of HK$25.58, 47% below the start price. This view stressed regulatory and pricing pressure in China and assumed a future P/E of 15.1x despite 53.9% revenue growth and 22.1% margins.
What The Everest Medicines Evidence Actually Tested
The licensing deals for civorebrutinib and DMX-200, plus Asia-Pacific rights to Bejescin, backed the view that Everest Medicines could broaden its kidney and autoimmune portfolio and use partnerships to support revenue. The H1 2026 update showed revenue of C¥1,147.84m and a loss of C¥5.944m, with net margin at -0.5%. The evidence pointed in both directions because profitability remained unproven.
The key lesson is simple. When an investment story leans on partnerships and margin lift, track the mix of licensing income versus product sales and the reported net margin trend to see whether those expectations appear in the financial results.
What Everest Medicines' Drop Asks You To Believe Today
Everest Medicines now trades at HK$26.46. The selected Narrative sees Fair Value above that level and leans on a broader multi-franchise platform, not just one drug, to frame that view.
For the fall to look like an opportunity rather than a warning, a buyer today would need confidence that Everest Medicines can build and defend a leading renal and autoimmune franchise while expanding newer pillars enough to support margins and cash-funded research.
"The main thing that has to go right is Everest Medicines successfully building a leading renal and autoimmune franchise around NEFECON and its broader nephrology portfolio, while managing competition and execution risks in China. The current valuation implies Everest Medicines is undervalued relative to its growing revenue base, high gross margin profile and the potential for further value from its mRNA, in vivo CAR-T and out-licensing activities."
One Narrative disagrees with today's price. → See where this Narrative says Everest Medicines should trade
Go Straight To The Source
This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.
- Company 1 - 45% below our estimate - uses digital channels and regulatory reform to pull retail borrowers into bundled banking services.
- Company 2 - 29% below our estimate - buys niche component makers and restructures them to pursue higher margin industrial applications.
- Company 3 - 23% below our estimate - sells subscription networking gear that keeps robots and remote sites online across multiple links.
That is three of the list. See all 198 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com